Recent Publications

  1. Amtul Z, Park JW, Murphy MP, Siddiqui RA, Choudhary MI (2013) Dietary lipids and Alzheimer's disease. Curr Alzheimer Res 10:542-548.
  2. Ansari MA, Roberts KN, Scheff S (2013) Dose and time dependent neuroprotective effects of Pycnogenol following traumatic brain injury. J Neurotrauma.
  3. Bachstetter AD, Rowe RK, Kaneko M, Goulding D, Lifshitz J, Van Eldik LJ (2013) The p38alpha MAPK regulates microglial responsiveness to diffuse traumatic brain injury. J Neurosci 33:6143-6153.
  4. Bag S, Ghosh S, Tulsan R, Sood A, Zhou W, Schifone C, Foster M, LeVine H, 3rd, Torok B, Torok M (2013) Design, synthesis and biological activity of multifunctional alpha,beta-unsaturated carbonyl scaffolds for Alzheimer's disease. Bioorg Med Chem Lett 23:2614-2618.
  5. Bix GJ (2013) Perlecan domain V therapy for stroke: a beacon of hope? ACS Chem Neurosci 4:370-374.
  6. Carty N, Nash KR, Brownlow M, Cruite D, Wilcock D, Selenica ML, Lee DC, Gordon MN, Morgan D (2013) Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice. PLoS One 8:e59626.
  7. Di Domenico F, Coccia R, Cocciolo A, Murphy MP, Cenini G, Head E, Butterfield DA, Giorgi A, Schinina ME, Mancuso C, Cini C, Perluigi M (2013) Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: Redox proteomics analysis of human brain. Biochim Biophys Acta 1832:1249-1259.
  8. Gold BT, Kim C, Johnson NF, Kryscio RJ, Smith CD (2013) Lifelong bilingualism maintains neural efficiency for cognitive control in aging. J Neurosci 33:387-396.
  9. Head E (2013) A canine model of human aging and Alzheimer's disease. Biochim Biophys Acta 1832:1384-1389.
  10. Hebert SS, Wang WX, Zhu Q, Nelson PT (2013) A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer's disease, dementia with lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls. J Alzheimers Dis 35:335-348.
  11. Jicha GA, Rentz DM (2013) Cognitive and brain reserve and the diagnosis and treatment of preclinical Alzheimer disease. Neurology 80:1180-1181.
  12. Kahle MP, Bix GJ (2013) Neuronal restoration following ischemic stroke: influences, barriers, and therapeutic potential. Neurorehabil Neural Repair 27:469-478.
  13. Kryscio RJ, Abner EL, Lin Y, Cooper GE, Fardo DW, Jicha GA, Nelson PT, Smith CD, Van Eldik LJ, Wan L, Schmitt FA (2013) Adjusting for mortality when identifying risk factors for transitions to mild cognitive impairment and dementia. J Alzheimers Dis 35:823-832.
  14. McBride J, Zhao X, Munro N, Smith C, Jicha G, Jiang Y (2013) Resting EEG discrimination of early stage Alzheimer's disease from normal aging using inter-channel coherence network graphs. Ann Biomed Eng 41:1233-1242.
  15. Murphy MP (2013) Special issue: Animal models of disease. Biochim Biophys Acta 1832:1361.
  16. Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo DW, Estus S, Rebeck GW (2013) APOE-[Latin Small Letter Open E]2 and APOE-[Latin Small Letter Open E]4 Correlate With Increased Amyloid Accumulation in Cerebral Vasculature. J Neuropathol Exp Neurol.
  17. Nicholson AM, Baker MC, Finch NA, Rutherford NJ, Wider C, Graff-Radford NR, Nelson PT, Clark HB, Wszolek ZK, Dickson DW, Knopman DS, Rademakers R (2013) CSF1R mutations link POLD and HDLS as a single disease entity. Neurology 80:1033-1040.
  18. Niedowicz DM, Studzinski CM, Weidner AM, Platt TL, Kingry KN, Beckett TL, Bruce-Keller AJ, Keller JN, Murphy MP (2013) Leptin regulates amyloid beta production via the gamma-secretase complex. Biochim Biophys Acta 1832:439-444.
  19. Platt TL, Reeves VL, Murphy MP (2013) Transgenic models of Alzheimer's disease: Better utilization of existing models through viral transgenesis. Biochim Biophys Acta 1832:1437-1448.
  20. Pop V, Sorensen DW, Kamper JE, Ajao DO, Murphy MP, Head E, Hartman RE, Badaut J (2013) Early brain injury alters the blood-brain barrier phenotype in parallel with beta-amyloid and cognitive changes in adulthood. J Cereb Blood Flow Metab 33:205-214.
  21. Rinker B, Fink BF, Stoker AR, Milan ME, Nelson PT (2013) Calcium channel blockers reduce the effects of cigarette smoking on peripheral nerve ischemia/reperfusion injury. Ann Plast Surg 70:222-226.
  22. Roher AE, Cribbs DH, Kim RC, Maarouf CL, Whiteside CM, Kokjohn TA, Daugs ID, Head E, Liebsack C, Serrano G, Belden C, Sabbagh MN, Beach TG (2013) Bapineuzumab alters abeta composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy. PLoS One 8:e59735.
  23. Sama DM, Norris CM (2013) Calcium dysregulation and neuroinflammation: Discrete and integrated mechanisms for age-related synaptic dysfunction. Ageing Res Rev.
  24. Scheff SW, Ansari MA, Roberts KN (2013) Neuroprotective effect of Pycnogenol(R) following traumatic brain injury. Exp Neurol 239:183-191.
  25. Scheff SW, Price DA, Schmitt FA, Roberts KN, Ikonomovic MD, Mufson EJ (2013) Synapse stability in the precuneus early in the progression of Alzheimer's disease. J Alzheimers Dis 35:599-609.
  26. Schnieders T, Danner DD, McGuire C, Reynolds F, Abner E (2013) Incentives and Barriers to Research Participation and Brain Donation Among African Americans. Am J Alzheimers Dis Other Demen.
  27. Sudduth TL, Greenstein A, Wilcock DM (2013) Intracranial Injection of Gammagard, a Human IVIg, Modulates the Inflammatory Response of the Brain and Lowers Abeta in APP/PS1 Mice Along a Different Time Course than Anti-Abeta Antibodies. J Neurosci 33:9684-9692.
  28. Sudduth TL, Powell DK, Smith CD, Greenstein A, Wilcock DM (2013) Induction of hyperhomocysteinemia models vascular dementia by induction of cerebral microhemorrhages and neuroinflammation. J Cereb Blood Flow Metab 33:708-715.
  29. Sudduth TL, Schmitt FA, Nelson PT, Wilcock DM (2013) Neuroinflammatory phenotype in early Alzheimer's disease. Neurobiol Aging 34:1051-1059.
  30. Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, Poon WW, Cornwell LB, Miller CA, Vinters HV, Van Eldik LJ, Fardo DW, Estus S, Bu G, Gylys KH, Ladu MJ (2013) Levels of soluble apolipoprotein E/amyloid-beta (Abeta) complex are reduced and oligomeric Abeta increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem 288:5914-5926.
  31. Torok B, Sood A, Bag S, Tulsan R, Ghosh S, Borkin D, Kennedy AR, Melanson M, Madden R, Zhou W, Levine H, 3rd, Torok M (2013) Diaryl hydrazones as multifunctional inhibitors of amyloid self-assembly. Biochemistry 52:1137-1148.
  32. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Trojanowski JQ, Weintraub D, Chen-Plotkin AS, Irwin DJ, Rick J, Schellenberg GD, Watson GS, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Quinn JF, Chung KA, Yearout D, Mata IF, Wan JY, Edwards KL, Montine TJ, Zabetian CP (2013) APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 70:223-228.
  33. Webster SJ, Bachstetter AD, Van Eldik LJ (2013) Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease. Alzheimers Res Ther 5:28.
  34. Xing B, Bachstetter AD, Van Eldik LJ (2013) Deficiency in p38beta MAPK fails to inhibit cytokine production or protect neurons against inflammatory insult in in vitro and in vivo mouse models. PLoS One 8:e56852.
  35. Zhang L, Dasuri K, Fernandez-Kim SO, Bruce-Keller AJ, Freeman LR, Pepping JK, Beckett TL, Murphy MP, Keller JN (2013) Prolonged diet induced obesity has minimal effects towards brain pathology in mouse model of cerebral amyloid angiopathy: Implications for studying obesity-brain interactions in mice. Biochim Biophys Acta 1832:1456-1462.
  36. Abner EL, Kryscio RJ, Cooper GE, Fardo DW, Jicha GA, Mendiondo MS, Nelson PT, Smith CD, Van Eldik LJ, Wan L, Schmitt FA (2012) Mild cognitive impairment: statistical models of transition using longitudinal clinical data. Int J Alzheimers Dis 2012:291920.
  37. Andersen AH, Rayens WS, Liu Y, Smith CD (2012) Partial least squares for discrimination in fMRI data. Magn Reson Imaging 30:446-452.
  38. Bachstetter AD, Norris CM, Sompol P, Wilcock DM, Goulding D, Neltner JH, St Clair D, Watterson DM, Van Eldik LJ (2012) Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology. J Neurosci 32:10201-10210.
  39. Barone E, Di Domenico F, Sultana R, Coccia R, Mancuso C, Perluigi M, Butterfield DA (2012) Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med 52:2292-2301.
  40. Barone E, Mancuso C, Di Domenico F, Sultana R, Murphy MP, Head E, Butterfield DA (2012) Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. J Neurochem 120:135-146.
  41. Blonder LX, Pettigrew CL, Kryscio RJ (2012) Emotion recognition and marital satisfaction in stroke. Journal of clinical and experimental neuropsychology.
  42. Butterfield DA, Barone E, Di Domenico F, Cenini G, Sultana R, Murphy MP, Mancuso C, Head E (2012) Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. Int J Neuropsychopharmacol 15:981-987.
  43. Butterfield DA, Perluigi M, Reed T, Muharib T, Hughes CP, Robinson RA, Sultana R (2012) Redox Proteomics in Selected Neurodegenerative Disorders: From Its Infancy to Future Applications. Antioxid Redox Signal.
  44. Caban-Holt A, Abner E, Kryscio RJ, Crowley JJ, Schmitt FA (2012) Age-expanded normative data for the ruff 2&7 selective attention test: evaluating cognition in older males. The Clinical neuropsychologist 26:751-768.
  45. Cenini G, Dowling AL, Beckett TL, Barone E, Mancuso C, Murphy MP, Levine H, 3rd, Lott IT, Schmitt FA, Butterfield DA, Head E (2012) Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta 1822:130-138.
  46. Clarke DN, Al Ahmad A, Lee B, Parham C, Auckland L, Fertala A, Kahle M, Shaw CS, Roberts J, Bix GJ (2012) Perlecan Domain V induces VEGf secretion in brain endothelial cells through integrin alpha5beta1 and ERK-dependent signaling pathways. PLoS One 7:e45257.
  47. Counts SE, He B, Nadeem M, Wuu J, Scheff SW, Mufson EJ (2012) Hippocampal Drebrin Loss in Mild Cognitive Impairment. Neurodegener Dis.
  48. Di Domenico F, Casalena G, Jia J, Sultana R, Barone E, Cai J, Pierce WM, Cini C, Mancuso C, Perluigi M, Davis CM, Alkayed NJ, Butterfield DA (2012) Sex differences in brain proteomes of neuron-specific STAT3-null mice after cerebral ischemia/reperfusion. J Neurochem 121:680-692.
  49. Di Domenico F, Sultana R, Ferree A, Smith K, Barone E, Perluigi M, Coccia R, Pierce W, Cai J, Mancuso C, Squillace R, Wiengele M, Dalle-Donne I, Wolozin B, Butterfield DA (2012) Redox Proteomics Analyses of the Influence of Co-Expression of Wild-Type or Mutated LRRK2 and Tau on C. elegans Protein Expression and Oxidative Modification: Relevance to Parkinson Disease. Antioxid Redox Signal.
  50. Ding Q, Zhu H, Zhang B, Soriano A, Burns R, Markesbery WR (2012) Increased 5S rRNA Oxidation in Alzheimer's Disease. J Alzheimers Dis.
  51. Duncan MJ, Smith JT, Franklin KM, Beckett TL, Murphy MP, St Clair DK, Donohue KD, Striz M, O'Hara BF (2012) Effects of aging and genotype on circadian rhythms, sleep, and clock gene expression in APPxPS1 knock-in mice, a model for Alzheimer's disease. Exp Neurol 236:249-258.
  52. Ferrari R, Mok K, Moreno JH, Cosentino S, Goldman J, Pietrini P, Mayeux R, Tierney MC, Kapogiannis D, Jicha GA, Murrell JR, Ghetti B, Wassermann EM, Grafman J, Hardy J, Huey ED, Momeni P (2012) Screening for C9ORF72 repeat expansion in FTLD. Neurobiol Aging 33:1850 e1851-1811.
  53. Furman JL, Sama DM, Gant JC, Beckett TL, Murphy MP, Bachstetter AD, Van Eldik LJ, Norris CM (2012) Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci 32:16129-16140.
  54. Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P (2012) Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 69:836-841.
  55. Gleichmann M, Zhang Y, Wood WH, 3rd, Becker KG, Mughal MR, Pazin MJ, van Praag H, Kobilo T, Zonderman AB, Troncoso JC, Markesbery WR, Mattson MP (2012) Molecular changes in brain aging and Alzheimer's disease are mirrored in experimentally silenced cortical neuron networks. Neurobiol Aging 33:205 e201-218.
  56. Gold BT, Jiang Y, Powell DK, Smith CD (2012) Multimodal Imaging Evidence for Axonal and Myelin Deterioration in Amnestic Mild Cognitive Impairment. J Alzheimers Dis.
  57. Gold BT, Johnson NF, Powell DK, Smith CD (2012) White matter integrity and vulnerability to Alzheimer's disease: Preliminary findings and future directions. Biochim Biophys Acta 1822:416-422.
  58. Gwon AR, Park JS, Arumugam TV, Kwon YK, Chan SL, Kim SH, Baik SH, Yang S, Yun YK, Choi Y, Kim S, Tang SC, Hyun DH, Cheng A, Dann CE, 3rd, Bernier M, Lee J, Markesbery WR, Mattson MP, Jo DG (2012) Oxidative lipid modification of nicastrin enhances amyloidogenic gamma-secretase activity in Alzheimer's disease. Aging Cell.
  59. Hack N, Jicha GA, Abell A, Dean D, Vitek JL, Berger JR (2012) Substantia nigra depigmentation and exposure to encephalitis lethargica. Ann Neurol 72:912-917.
  60. Head E, Silverman W, Patterson D, Lott IT (2012) Aging and Down syndrome. Curr Gerontol Geriatr Res 2012:412536.
  61. Holler CJ, Webb RL, Laux AL, Beckett TL, Niedowicz DM, Ahmed RR, Liu Y, Simmons CR, Dowling AL, Spinelli A, Khurgel M, Estus S, Head E, Hersh LB, Murphy MP (2012) BACE2 expression increases in human neurodegenerative disease. Am J Pathol 180:337-350.
  62. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8:1-13.
  63. Ivanchak N, Fletcher K, Jicha GA (2012) Attention-deficit/hyperactivity disorder in older adults: prevalence and possible connections to mild cognitive impairment. Curr Psychiatry Rep 14:552-560.
  64. Jayaraman A, Carroll JC, Morgan TE, Lin S, Zhao L, Arimoto JM, Murphy MP, Beckett TL, Finch CE, Brinton RD, Pike CJ (2012) 17beta-estradiol and progesterone regulate expression of beta-amyloid clearance factors in primary neuron cultures and female rat brain. Endocrinology 153:5467-5479.
  65. Jicha GA, Abner EL, Schmitt FA, Kryscio RJ, Riley KP, Cooper GE, Stiles N, Mendiondo MS, Smith CD, Van Eldik LJ, Nelson PT (2012) Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging 33:622 e621-622 e616.
  66. Jung KM, Astarita G, Yasar S, Vasilevko V, Cribbs DH, Head E, Cotman CW, Piomelli D (2012) An amyloid beta42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. Neurobiol Aging 33:1522-1532.
  67. Kahle MP, Bix GJ (2012) Successfully Climbing the "STAIRs": Surmounting Failed Translation of Experimental Ischemic Stroke Treatments. Stroke Res Treat 2012:374098.
  68. Kahle MP, Lee B, Pourmohamad T, Cunningham A, Su H, Kim H, Chen Y, McCulloch CE, Barbaro NM, Lawton MT, Young WL, Bix GJ (2012) Perlecan domain V is upregulated in human brain arteriovenous malformation and could mediate the vascular endothelial growth factor effect in lesional tissue. Neuroreport 23:627-630.
  69. Liang C, Chan KH, Yoon PJ, Lovell MA (2012) Clinicopathological characteristics of extramedullary acute megakaryoblastic leukemia (AMKL): report of a case with initial mastoid presentation and review of literature to compare extramedullary AMKL and non-AMKL cases. Pediatr Dev Pathol 15:385-392.
  70. Ling IF, Bhongsatiern J, Simpson JF, Fardo DW, Estus S (2012) Genetics of clusterin isoform expression and Alzheimer's disease risk. PLoS One 7:e33923.
  71. Migongo AW, Charnigo R, Love MM, Kryscio R, Fleming ST, Pearce KA (2012) Factors relating to patient visit time with a physician. Med Decis Making 32:93-104.
  72. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 123:1-11.
  73. Mufson EJ, Binder L, Counts SE, DeKosky ST, de Toledo-Morrell L, Ginsberg SD, Ikonomovic MD, Perez SE, Scheff SW (2012) Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol 123:13-30.
  74. Mufson EJ, He B, Nadeem M, Perez SE, Counts SE, Leurgans S, Fritz J, Lah J, Ginsberg SD, Wuu J, Scheff SW (2012) Hippocampal proNGF signaling pathways and beta-amyloid levels in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol 71:1018-1029.
  75. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362-381.
  76. Neltner JH, Abner EL, Schmitt FA, Denison SK, Anderson S, Patel E, Nelson PT (2012) Digital pathology and image analysis for robust high-throughput quantitative assessment of Alzheimer disease neuropathologic changes. J Neuropathol Exp Neurol 71:1075-1085.
  77. Niedowicz DM, Beckett TL, Matveev S, Weidner AM, Baig I, Kryscio RJ, Mendiondo MS, LeVine H, 3rd, Keller JN, Murphy MP (2012) Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease. Ann Neurol 72:564-570.
  78. Ridnour LA, Dhanapal S, Hoos M, Wilson J, Lee J, Cheng RY, Brueggemann EE, Hines HB, Wilcock DM, Vitek MP, Wink DA, Colton CA (2012) Nitric oxide-mediated regulation of beta-amyloid clearance via alterations of MMP-9/TIMP-1. J Neurochem 123:736-749.
  79. Roberts J, Kahle MP, Bix GJ (2012) Perlecan and the blood-brain barrier: beneficial proteolysis? Front Pharmacol 3:155.
  80. Santa-Maria I, Haggiagi A, Liu X, Wasserscheid J, Nelson PT, Dewar K, Clark LN, Crary JF (2012) The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol 124:693-704.
  81. Schmitt FA, Nelson PT, Abner E, Scheff S, Jicha GA, Smith C, Cooper G, Mendiondo M, Danner DD, Van Eldik LJ, Caban-Holt A, Lovell MA, Kryscio RJ (2012) University of Kentucky Sanders-Brown Healthy Brain Aging Volunteers: Donor Characteristics, Procedures, and Neuropathology. Curr Alzheimer Res.
  82. Smith CD (2012) Structural imaging in early pre-states of dementia. Biochim Biophys Acta 1822:317-324.
  83. Smith CD, Andersen AH, Gold BT (2012) Structural Brain Alterations before Mild Cognitive Impairment in ADNI: Validation of Volume Loss in a Predefined Antero-Temporal Region. J Alzheimers Dis.
  84. Sudduth TL, Wilson JG, Everhart A, Colton CA, Wilcock DM (2012) Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype. PLoS One 7:e31993.
  85. Swerdlow RH, Jicha GA (2012) Alzheimer disease: Can the exam predict the pathology? Neurology.
  86. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Trojanowski JQ, Schellenberg GD, Yearout D, Huston H, Fritts-Penniman A, Mata IF, Wan JY, Edwards KL, Montine TJ, Zabetian CP (2012) GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology 79:1944-1950.
  87. Walker LC, LeVine H, 3rd (2012) Corruption and spread of pathogenic proteins in neurodegenerative diseases. J Biol Chem 287:33109-33115.
  88. Wilcock DM (2012) A changing perspective on the role of neuroinflammation in Alzheimer's disease. Int J Alzheimers Dis 2012:495243.
  89. Wilcock DM (2012) Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease. Current gerontology and geriatrics research 2012:170276.
  90. Wright S, Parham C, Lee B, Clarke D, Auckland L, Johnston J, Lawrence AL, Dickeson SK, Santoro SA, Griswold-Prenner I, Bix G (2012) Perlecan domain V inhibits alpha2 integrin-mediated amyloid-beta neurotoxicity. Neurobiol Aging 33:1379-1
  91. Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, Kim J, Eimer WA, Estus S, Rebeck GW, Weeber EJ, Bu G, Yu C, Ladu MJ (2012) APOE4-specific changes in Abeta accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem 287:41774-41786